Literature DB >> 22672218

Pharmacologic preconditioning therapy prior to atrial septal defect closure in patients at high risk for acute pulmonary edema.

Christiane Gruner1, Ersan Akkaya, Oliver Kretschmar, Marco Roffi, Roberto Corti, Rolf Jenni, Franz R Eberli.   

Abstract

OBJECTIVES: The aim of this study was to assess whether transient atrial septal defect (ASD) occlusion and, if required, vasodilator therapy would improve the safety of percutaneous ASD closure in high-risk subsets.
BACKGROUND: While percutaneous ASD closure is generally considered a low risk intervention, hypertensive and elderly patients may develop pulmonary edema following the procedure because of underlying left ventricular (LV) diastolic dysfunction.
METHODS: Fifty-two consecutive patients who underwent successful percutaneous ASD closures were enrolled into a single-center prospective registry. Patients with arterial hypertension and/or >60 years of age (n = 15) were considered at risk for periprocedural pulmonary edema. Those patients were tested for an increase of LV filling pressures during transient ASD occlusion and, if this was the case, treated according to a prespecified algorithm. Clinical and echocardiography data were collected in-hospital and at 6 months follow-up.
RESULTS: Shunt size was comparable in high and standard-risk patients (Qp:Qs 2.1 ± 0.8 vs. 2.1 ± 0.7, P = 0.82). High-risk patients had more often pulmonary hypertension (58% vs. 14%, P < 0.05) and were more frequently symptomatic. Among them, 4/15 (27%) demonstrated a significant rise of left-sided filling pressures during transient ASD balloon occlusion and underwent pharmacologic preconditioning prior to ASD closure. None of them developed periprocedural pulmonary edema. At follow-up, patients were less symptomatic (Pre: NYHA II n = 15, NYHA III n = 9; Post: NYHA II n = 15, NYHA III n = 0; P = 0.02) and right ventricular size decreased from 23 ± 5 cm(2) to 17 ± 5 cm(2), P < 0.05.
CONCLUSION: Transient ASD occlusion and, if required, pharmacologic preconditioning prior to percutaneous closure may prevent periprocedural pulmonary edema in high-risk patients. ©2012, Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672218     DOI: 10.1111/j.1540-8183.2012.00747.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  8 in total

1.  Sox18 preserves the pulmonary endothelial barrier under conditions of increased shear stress.

Authors:  Christine M Gross; Saurabh Aggarwal; Sanjiv Kumar; Jing Tian; Anita Kasa; Natalia Bogatcheva; Sanjeev A Datar; Alexander D Verin; Jeffrey R Fineman; Stephen M Black
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

2.  ASD closure under pressure.

Authors:  Suhair Omar Shebani; Gregory James Skinner; Christopher Duke
Journal:  BMJ Case Rep       Date:  2014-09-11

Review 3.  Hemodynamic assessment of atrial septal defects.

Authors:  Alejandro Javier Torres
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Left ventricular restrictive physiology in kids with atrial septal defects: Something unexpected!

Authors:  Alessia Faccini; Matteo Casenghi; Mario Carminati; Gianfranco Butera
Journal:  Ann Pediatr Cardiol       Date:  2021-04-10

5.  Pulmonary edema following transcatheter closure of atrial septal defect.

Authors:  Keerthi Chigurupati; Liza Jose Reshmi; Shrinivas Gadhinglajkar; S Venkateshwaran; Rupa Sreedhar
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

6.  Efficacy and safety of transcatheter closure in adults with large or small atrial septal defects.

Authors:  Matthias R Meyer; David J Kurz; Alain M Bernheim; Oliver Kretschmar; Franz R Eberli
Journal:  Springerplus       Date:  2016-10-21

7.  Effectiveness and Safety of Transcatheter Atrial Septal Defect Closure in Adults with Systemic Essential Hypertension.

Authors:  Iwona Świątkiewicz; Łukasz Bednarczyk; Michał Kasprzak; Ewa Laskowska; Marek Woźnicki
Journal:  J Clin Med       Date:  2022-02-13       Impact factor: 4.241

8.  The ERK1/2 signaling pathway is involved in sulfur dioxide preconditioning-induced protection against cardiac dysfunction in isolated perfused rat heart subjected to myocardial ischemia/reperfusion.

Authors:  Pan Huang; Yan Sun; Jinyan Yang; Siyao Chen; Angie Dong Liu; Lukas Holmberg; Xiaomei Huang; Chaoshu Tang; Junbao Du; Hongfang Jin
Journal:  Int J Mol Sci       Date:  2013-11-08       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.